- Oops!Something went wrong.Please try again later.
Walgreens Boots Alliance, Inc. WBA is slated to release third-quarter fiscal 2021 results on Jul 1, before market open.
In the fiscal second quarter, the company reported an earnings surprise of 27.3%. Over the trailing four quarters, its earnings outperformed the Zacks Consensus Estimate on three occasions and missed in one, the average surprise being 7.15%.
Let’s take a look at how things have shaped up prior to this announcement.
Factors at Play
Walgreens shifted a major part of its business to the digital platform, given the unrelenting continuation of the pandemic. The company’s Find Care platform continues to grow, accelerated by the pandemic and witnessing significant increase in online visits. Notably, the company also introduced COVID vaccination booking on the myWalgreens app. These developments are expected to have accelerated the company’s digital platform growth in the fiscal third quarter, thus adding to the top line.
Retail Pharmacy USA
In the fiscal third quarter, Walgreens is expected to have witnessed a rebound in retail pharmacy business due to improved business environment amid post-pandemic recovery. The company continues to engage customers through the mass personalization strategy, which boosted retail sales during the last-reported quarter. The new loyalty program, myWalgreens, providing all members with new loyalty benefits, personalized products and services, is expected to have once again driven customer adoption rate in the to-be-reported quarter.
In the earlier-reported quarter, the company noted continued strength in health and wellness over the past few months. This favorable trend is likely to have continued through the fiscal third quarter driven by increased health consciousness stemming from the pandemic-led crisis, thus boosting the company’s top line. In April 2021, Walgreens launched No7 Beauty Company, which will be positioned to develop omnichannel offerings. This development is likely to have contributed to Walgreens’ health and beauty businesses in the to-be reported quarter as well.
Walgreens Boots Alliance, Inc. Price and EPS Surprise
Walgreens Boots Alliance, Inc. price-eps-surprise | Walgreens Boots Alliance, Inc. Quote
The Zacks Consensus Estimate for Retail Pharmacy USA’s revenues is pegged at $29.47 billion, suggesting a rise of 7.7% from the year-ago quarter’s reported figure.
Retail Pharmacy International
In the earlier-reported quarter, international business outperformed expectations due to focused execution, notably in Boots, U.K., Ireland and Opticians, led by strong growth across all e-commerce businesses. The reopening of economy and faster adoption of digital platform are expected to have accelerated international businesses in the to-be reported quarter.
During the company’s February 2021 update, Walgreens noted that the launch of Boots online Health Hub is conveniently connecting customers to all Boots' existing healthcare services as well as an increasing local doctors, therapists and dermatologists. Boots.com is likely to have continued with its stellar performance on increasing digital transactions and launch of new platform, thus driving revenues in the to-be-reported quarter.
The Zacks Consensus Estimate for Retail Pharmacy International’s revenues is pegged at $2.38 billion, suggesting a surge of 25% from the year-ago quarter’s reported figure.
The Pharmaceutical Wholesale division has been performing quite impressively over the past few months. In the last-reported quarter, the segment registered robust growth despite the pandemic-led business challenges, including results of the company's new joint venture in Germany. The company has also been gaining from sales growth in emerging markets over the past few months. These developments are anticipated to have significantly contributed to the company’s fiscal third-quarter performance.
The Zacks Consensus Estimate for Pharmaceutical Wholesale’s revenues is pegged at $6.19 billion, suggesting a rise of 5% from the last-reported quarter’s reported figure.
What Our Model Suggests
Our proven model predicts an earnings beat for Walgreens this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), #2 (Buy) or #3 (Hold) increases the chances of an earnings beat.
Earnings ESP: Walgreens has an Earnings ESP of +8.62%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #3.
Other Stocks Worth a Look
Here are a few medical stocks worth considering as these have the right combination of elements to beat on earnings this reporting cycle.
BioNTech SE Sponsored ADR BNTX has an Earnings ESP of +63.80% and a Zacks Rank of 1, at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Henry Schein, Inc. HSIC has an Earnings ESP of +6.87% and a Zacks Rank of 1, at present.
Bellerophon Therapeutics, Inc. BLPH has an Earnings ESP of +8.63% and a Zacks Rank of 2, at present.
Bitcoin, Like the Internet Itself, Could Change Everything
Blockchain and cryptocurrency has sparked one of the most exciting discussion topics of a generation. Some call it the “Internet of Money” and predict it could change the way money works forever. If true, it could do to banks what Netflix did to Blockbuster and Amazon did to Sears. Experts agree we’re still in the early stages of this technology, and as it grows, it will create several investing opportunities.
Zacks’ has just revealed 3 companies that can help investors capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly.
See 3 crypto-related stocks now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Henry Schein, Inc. (HSIC) : Free Stock Analysis Report
Walgreens Boots Alliance, Inc. (WBA) : Free Stock Analysis Report
Bellerophon Therapeutics, Inc. (BLPH) : Free Stock Analysis Report
BioNTech SE Sponsored ADR (BNTX) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research